Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Novartis and the Big Data Institute establish world-leading research alliance using artificial intelligence to understand complex diseases and improve drug development.

Novartis today announced a five-year collaboration with the Big Data Institute (BDI) to establish a world-leading research alliance that will improve drug development by making it more efficient and more targeted.  Using artificial intelligence (AI) and advanced analytics, the partners expect to transform how ultra large and multiple datasets are analysed, combined and interpreted to identify early predictors of patient responses to treatments for inflammatory diseases, such as multiple sclerosis (MS) and psoriasis.

Read more (Big Data Institute website)